In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249

Carcinogenesis

Volumn 29, Issue 7, 2008, Pages 1428-1434

  Shi, Hong ^a   Lambert, Jeremy M R ^a,b   Hautefeuille, Agnes ^a   Bykov, Vladimir J N ^b   Wiman, Klas G ^b   Hainaut, Pierre ^a   de Fromentel, Claude Caron ^c  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; GLUTAMINE; PROTEIN P53; PROTEIN P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS PROTEIN 1; SERINE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; GENE ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TRANSACTIVATION; WILD TYPE;

ANIMALS; APOPTOSIS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL NUCLEOLUS; DNA, NEOPLASM; GENE SILENCING; HUMANS; LIVER NEOPLASMS; MICE; MICE, SCID; MUTATION; RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 49449110198     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm266     Document Type: Article

References (29)

1. Ferlay,J. et al. (2004) GLOBOCAN 2002; Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, Version 2.0. IARCPress, Lyon. http://www-dep.iarc.fr. (16 December 2007, date last accessed).
2. Kew,M.C. (2003) Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int., 23, 405-409.
3. Llovet,I.M. et al. (2003) Hepatocellular carcinoma. Lancet, 362, 1907-1917.
4. Bruix,J. et al. (2006) New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene, 25, 3848-38546.
5. Llovet,J.M. et al. (2000) Nonsurgical treatment of hepatocellular carcinoma. Liver Transpl., 6, S11-S15.
6. Dawson,L.A. et al. (2005) Partial volume tolerance of the liver to radiation. Semin. Radiat. Oncol., 15, 279-283.
7. Bressac,B. et al. (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 350, 429-431.
8. Hsu,I.C. et al. (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 350, 427-428.
9. Shen,H.M. et al. (1996) Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat. Res., 366, 23-44.
10. Aguilar,F. et al. (1993) Aflatoxin B1 induces the transversion of G->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl Acad. Sci. USA, 90, 8586-8590.
11. Mace,K. et al. (1997) Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis, 18, 1291-1297.
12. Vousden,K.H. et al. (2002) Live or let die: The cell's response to p53. Nat. Rev. Cancer, 2, 594-604.
13. Olivier,M. et al. (2002) The IARC TP53 database: New online mutation analysis and recommendations to users. Hum. Mutat., 19 607-614.
14. Petitjean,A. et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat. 28 622-629.
15. Bykov,V.J. et al. (2002) Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: A statistical analysis of information in the National Cancer Institute database. Carcinogenesis, 23, 2011-2018.
16. Bykov,V.J. et al. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular- weight compound. Nat. Med. 8, 282-288.
17. Wang,T. et al. (2007) PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. Biochem. Biophys. Res. Commun., 352, 203-212.
18. Bressac,B. et al. (1990) Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl Acad. Sci. USA, 87, 1973-1977.
19. Puisieux,A. et al. (1993) Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J., 7, 1407-1413.
20. Murakami,Y. et al. (1991) Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res., 51, 3356-3361.
21. Erster,S. et al. (2004) In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol. Cell. Biol., 24, 6728-6741.
22. Schagger,H. (2006) Tricine-SDS-PAGE. Nat. Protoc., 1, 16-22.
23. Benoit,V. et al. (2006) Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene, 25, 5708-5718.
24. Rokaeus,N. et al. (2007) PRIMA-I(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins. Oncogene, 26, 982-992.
25. Bullock,A.N. et al. (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy. Oncogene, 19, 1245-1256.
26. Cho,Y. et al. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 346-355.
27. Chipuk,J.E. et al. (2003) Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence oftranscription. Cancer Cell 4, 371-381.
28. Cadwell,C. et al. (2001) The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene, 277, 15-30.
29. Li,Y. et al. (2007) Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene, 26, 2220-2225.